Aptevo Therapeutics (APVO) Receives Daily Media Impact Rating of 0.20

News coverage about Aptevo Therapeutics (NASDAQ:APVO) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.6416303872564 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment’s scoring:

A number of research analysts have recently issued reports on APVO shares. ValuEngine lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 30th. Zacks Investment Research downgraded shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $11.00 price objective on shares of Aptevo Therapeutics in a report on Friday.

APVO stock traded up $0.33 during trading on Friday, reaching $4.83. 165,100 shares of the company were exchanged, compared to its average volume of 119,934. The company has a market cap of $101.64 million, a P/E ratio of -3.16 and a beta of 0.21. Aptevo Therapeutics has a 52-week low of $1.15 and a 52-week high of $6.35. The company has a current ratio of 4.47, a quick ratio of 4.39 and a debt-to-equity ratio of 0.20.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. The business had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $4.17 million. equities research analysts expect that Aptevo Therapeutics will post -2.63 earnings per share for the current year.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Further Reading: Market Capitalization and Individual Investors

Insider Buying and Selling by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply